Home Featured Page 172

Featured

Latest

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120...

Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional...

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120...

FILAMENT HEALTH APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS AND ADVISORY...

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic...

Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction...

Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position

GH Research Reports Second Quarter 2022 Financial Results and Provides Business...

PT349 – Brenna Gebauer – Slowing Down, The Ethics of Touch,...

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Who Gets to Heal?

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120...

Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional...

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120...

FILAMENT HEALTH APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS AND ADVISORY...

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic...

Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction...

Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position

GH Research Reports Second Quarter 2022 Financial Results and Provides Business...

PT349 – Brenna Gebauer – Slowing Down, The Ethics of Touch,...

Interview | Josh Ismin, Psylo

EDITOR PICKS

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY